Proxy Votes Now

Home › Funds › AdvisorShares Psychedelics ETF

AdvisorShares Psychedelics ETF (PSIL) proxy voting record 2025-2026

Fund family: AdvisorShares Trust · Filed by AdvisorShares Trust (CIK 1408970) · SEC series S000072085

Ticker: PSIL (C000227806)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 200 with, 4 against, 0 abstentions (not counted as with management); 9 items carried no recommendation. Shareholder proposals: 1 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other AdvisorShares Trust funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1232
Audit-related280
Capital Structure160
Compensation150
Say-on-Pay140
Corporate Governance122
Extraordinary Transactions40
Other20

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Compass Pathways PlcMay 27, 2026$2M100
Neurocrine Biosciences, Inc.May 27, 2026$1M60
AbbVie Inc.May 8, 2026$1M81
Johnson & JohnsonApril 23, 2026$955,434151
Neuronetics, Inc.May 28, 2026$393,354100

Notable votes against management

MeetingCompanyProposalFundMgmt
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
December 12, 2025Neuphoria Therapeutics Inc.Election of two Class I directors to serve for a three-year term of office expiring at the 2028 Annual Meeting of Shareholders. While you may mark instructions with respect to any or all of the nominees, you may mark "FOR" only in respect of two nominees in total. You are permitted to vote for fewer than two nominees. If you vote "FOR" in respect of fewer than two nominees, your shares will only be voted "FOR" in respect of the nominee you have marked. If you vote "FOR" in respect of more than two nominees, your votes on Proposal 1 regarding director elections will be invalid or will not be counted. If you sign and return your proxy card and do not specify how you want your shares to be voted, they will be voted "FOR" in respect of all the Company nominees. LYNX1 Nominees: Stephen Doberstein Shareholder proposalWithholdFor
December 12, 2025Neuphoria Therapeutics Inc.Election of two Class I directors to serve for a three-year term of office expiring at the 2028 Annual Meeting of Shareholders. While you may mark instructions with respect to any or all of the nominees, you may mark "FOR" only in respect of two nominees in total. You are permitted to vote for fewer than two nominees. If you vote "FOR" in respect of fewer than two nominees, your shares will only be voted "FOR" in respect of the nominee you have marked. If you vote "FOR" in respect of more than two nominees, your votes on Proposal 1 regarding director elections will be invalid or will not be counted. If you sign and return your proxy card and do not specify how you want your shares to be voted, they will be voted "FOR" in respect of all the Company nominees. LYNX1 Nominees: Kimberly Smith Shareholder proposalWithholdFor

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

214 ballot items at 28 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, AdvisorShares Psychedelics ETF (PSIL) voted at 28 shareholder meetings of 25 companies, on 214 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 4 times. Its most frequent area of disagreement was director elections (2 of its votes against management). It voted on 6 shareholder proposals. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.